<DOC>
	<DOCNO>NCT00541554</DOCNO>
	<brief_summary>This prospective , open-label study evaluate efficacy safety reduce antipsychotic-induced hyperprolactinemia , weight gain , dyslipidemia aripiprazole . Approximate 60 patient recruit achieve least 40 evaluable patient .</brief_summary>
	<brief_title>Reversal Antipsychotic-Induced Hyperprolactinemia , Weight Gain , Hyperglycemia Dyslipidemia</brief_title>
	<detailed_description>A.Screening / Baseline visit ( V1 ; Day 0 ) After sign informed consent form , patient ' DSM-IV multiaxial examination , physical examination , vital sign , pregnancy test , BMI conduct . The demographic , medical history , concomitant medication record . After evaluate variable obtain , eligible patient enrol study.Patients fulfill inclusion / exclusion criterion perform laboratory test , PANSS , EPS ( AIMS &amp; BARS ) , menstrual function , sexual function ( Arizona sexual experience scale ) prolaction . Afterwards , treatment period start add-on first medication ( 7.5 15 mg daily patient , prescribed investigator ) current antipsychotic visit . Besides , drug accounting adverse event also record visit . Patients maintain current dos antipsychotic , medicine . B.Treatment phase ( V2~V3 ; 2~4 Week finish ; 14±3~28±3 Day finish ) The vital sign , physical examination , BMI , laboratory test ( V3 ) , PANSS , EPS ( AIMS &amp; BARS ) , menstrual function , sexual function ( Arizona sexual experience scale ) , prolactin carry . Concomitant medication , adverse event , drug accounting also record visit . Study drug could titrate flexible dose 7.5 30 mg QD . All dose adjustment make approval investigator . C.Completion visit ( V4 ; 8 Week Finished ; 56±7 Day finish , Early termination ) The vital sign , physical examination , pregnancy test , BMI , laboratory test , PANSS , EPS ( AIMS &amp; BARS ) , menstrual function , sexual function ( Arizona sexual experience scale ) , prolactin carry . Concomitant medication , adverse event , drug accounting also record visit .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Hyperprolactinemia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>1 . Male female age 12 65 year old . 2 . Clinical diagnosis schizophrenia , schizoaffective disorder , bipolar disorder DSMIV criterion . 3 . Keep stable dosage antipsychotic aripiprazole last one month . 4. Who currently take antipsychotic drug alteration medication clinically reasonable . This include patient stable symptom optimally control patient experience tolerability problem . 5 . Having antipsychoticinduced symptomatic hyperprolactinemia , weight gain , increase plasma glucose dyslipidemia judge investigator . 6 . Informed Consent obtain subject legal guardian ( necessary ) . 1 . Pregnant breast feed woman plan pregnancy . 2 . Patient history hypersensitivity allergy investigated drug . 3 . Acute psychosis , acute suicidal ideation , acute psychiatric condition might require emergent intervention . 4 . Any clinical condition significant concurrent disease judge investigator complicate evaluation study treatment . 5 . Having participated investigational drug study take investigation drug within one month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>